BGLC BioNexus Gene Lab Corp

Subscribe to $BGLC

BioNexus Gene Lab Corp

Subscribe to $BGLC

$BGLC

Medical Specialities

Health Care

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for BioNexus Gene Lab Corp

Date	Price Target	Rating	Analyst

See more ratings

BioNexus Gene Lab Corp Press Releases

Fastest customizable press release news feed in the world

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (NASDAQ:BGLC, the "Company"))), and Protech Builders Sdn. Bhd. ("Protech"), a leading mechanical and electrical engineering construction firm in Malaysia, are pleased to announce the signing of a strategic teaming agreement (the "Agreement") to jointly develop and operate biogas plants across Malaysia. This collaboration marks a significant step in both companies' efforts to contribute to Malaysia's growing renewable energy sector, particularly in the generation of biogas from plantation wastewater. Strategic Collaboration for Sustainable Growth Under thi
9/25/24 11:31:33 AM ET
$BGLC
Medical Specialities
Health Care
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC, the "Company"))), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. ("MRNA Scientific"), has entered into a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. ("Vitarray"), an exempted private company incorporated in Singapore. This agreement focuses on the provision of mRNA dynamic gene detection services for the Southeast Asian market. Under this agreement, MRNA Scientific will leverage its advanced medical testing facilities located in Kuala Lumpur, Malaysia, to provide
9/13/24 12:05:16 PM ET
$BGLC
Medical Specialities
Health Care
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC, the "Company"))), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU) with Shenzhen Rongguang Health Group, a major healthcare services provider in China. This partnership aims to expand the Company's expertise and presence in cancer screening, precision medicine, and preventative healthcare through its subsidiary MRNA Scientific Sdn Bhd. The partnership between the Company and Shenzhen Rongguang Health Group represents a significant step forward in developing advanced he
9/12/24 1:23:25 PM ET
$BGLC
Medical Specialities
Health Care
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (NASDAQ:BGLC, the "Company"))), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximately RM 2 million (approx. USD $450,000) to begin the production of fine-quality color paste (non-drying type) specifically designed for composite industrial customers. The new production facility will commence operations in late September 2024, marking a significant milestone for the Company as it seeks to expand its portfolio and enhance its market presence globally. The investment and the launch of this new product line will all
9/11/24 11:05:05 AM ET
$BGLC
Medical Specialities
Health Care
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction and potential of AISB. AISB, a pioneering healthcare technology company, has become the first issuer to receive investment under the Environmental & Social Impact (ESI) scheme, part of t
8/27/24 11:35:33 AM ET
$BGLC
Medical Specialities
Health Care
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC's wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC's commitment to advancing AI-driven healthcare solutions. AISB specializes in innovative healthcare technologies, particularly through its flagship platform, aiCMS, which integrates advanced predictive analytics and AI tools to enhance c
8/26/24 12:15:11 PM ET
$BGLC
Medical Specialities
Health Care
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
KUALA LUMPUR, Malaysia, April 19, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ:BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics. Background: MRNA Scientific Sdn Bhd: A wholly-owned subsidiary of BGLC, MRNA Scientific specializes in blood-based genomic screening and dynamic genome profiling.MRNA's innovative techniques enable early disease detection, pe
4/18/24 2:52:56 PM ET
$BGLC
Medical Specialities
Health Care
BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market
KUALA LUMPUR, Malaysia, July 24, 2023 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BioNexus" or the "Company") (NASDAQ:BGLC), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis and personalized health management, today announced the closing of an underwritten public offering (the "Offering") of 1,437,500 shares of common stock, including 187,500 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The Offering was priced at $4.00 per share for total gross proceeds of $5.75 million before deducting underwrit
7/24/23 11:30:00 AM ET
$BGLC
Medical Specialities
Health Care

BioNexus Gene Lab Corp

Recent Analyst Ratings for BioNexus Gene Lab Corp

BioNexus Gene Lab Corp

Recent Analyst Ratings for BioNexus Gene Lab Corp

BioNexus Gene Lab Corp SEC Filings

BioNexus Gene Lab Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

SEC Form 10-Q filed by BioNexus Gene Lab Corp

SEC Form NT 10-Q filed by BioNexus Gene Lab Corp

BioNexus Gene Lab Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

BioNexus Gene Lab Corp filed SEC Form 8-K: Leadership Update

BioNexus Gene Lab Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

BioNexus Gene Lab Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEF 14A filed by BioNexus Gene Lab Corp

BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

BioNexus Gene Lab Corp Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by BioNexus Gene Lab Corp

BioNexus Gene Lab Corp Press Releases

Fastest customizable press release news feed in the world

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market

BioNexus Gene Lab Corp Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Wong Yee Meng

SEC Form 3 filed by new insider Yap Chee Keong

SEC Form 3 filed by new insider Yew Chak Hua

SEC Form 3 filed by new insider Lin Chai Ping

SEC Form 3 filed by new insider Teoh Boon Teong

SEC Form 3 filed by new insider Fong Yeat Min

SEC Form 3 filed by new insider Yeoh Sook Keng

New insider Leong Wei Li claimed ownership of 4,797,709 shares (SEC Form 3)

New insider Liong Tai Tan claimed ownership of 12,500,460 shares (SEC Form 3)

SEC Form 3 filed by new insider Fong Teng Fook